Literature DB >> 15254208

Inhibition of infection and replication of human herpesvirus 8 in microvascular endothelial cells by alpha interferon and phosphonoformic acid.

Laurie T Krug1, Veronika P Pozharskaya, Yimin Yu, Naoki Inoue, Margaret K Offermann.   

Abstract

Infection of endothelial cells with human herpesvirus 8 (HHV-8) is an essential event in the development of Kaposi's sarcoma. When primary microvascular endothelial cells (MECs) were infected with HHV-8 at a low multiplicity of infection, considerable latent replication of HHV-8 occurred, leading to a time-dependent increase in the percentage of virus-infected cells that was accompanied by cellular spindling and growth to a high density with loss of contact inhibition. Only a low percentage of MECs supported lytic replication of HHV-8 and produced infectious virus. Phosphonoformic acid blocked production of infectious virus but did not inhibit the rapid expansion of latently infected MECs. Pretreatment of MECs with alpha interferon (IFN-alpha) prior to infection effectively reduced HHV-8 viral gene expression, latent replication, and production of infectious virus. High levels of the double-stranded RNA activated protein kinase (PKR) were expressed in HHV-8-infected cells, and incubation with IFN-alpha increased PKR expression more in virus-infected cells than in uninfected cells. MECs that were immortalized with simian virus 40 large-T antigen differed from nonimmortalized MECs in their response to infection with HHV-8 and demonstrated that cells with elevated levels of expression of antiviral transcripts expressed viral transcripts at reduced levels. These studies demonstrate that MECs respond to HHV-8 with enhanced expression of cellular antiviral genes and that augmentation of innate antiviral defenses with IFN-alpha is a more effective strategy than inhibition of viral lytic replication to protect MECs from infection with HHV-8 and to restrict proliferation of virus-infected MECs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254208      PMCID: PMC446096          DOI: 10.1128/JVI.78.15.8359-8371.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  91 in total

1.  Quantitation of cell-free and cell-associated Kaposi's sarcoma-associated herpesvirus DNA by real-time PCR.

Authors:  I E White; T B Campbell
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

2.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

Authors:  C Parravicini; B Chandran; M Corbellino; E Berti; M Paulli; P S Moore; Y Chang
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 4.  Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease.

Authors:  J S Butel
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

5.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells.

Authors:  M A Cotter; E S Robertson
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

6.  Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8.

Authors:  A V Moses; K N Fish; R Ruhl; P P Smith; J G Strussenberg; L Zhu; B Chandran; J A Nelson
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells.

Authors:  M Stürzl; C Hohenadl; C Zietz; E Castanos-Velez; A Wunderlich; G Ascherl; P Biberfeld; P Monini; P J Browning; B Ensoli
Journal:  J Natl Cancer Inst       Date:  1999-10-20       Impact factor: 13.506

8.  Expression of human herpesvirus-8 (HHV-8) encoded pathogenic genes in Kaposi's sarcoma (KS) primary lesions.

Authors:  G Ascherl; C Hohenadl; P Monini; C Zietz; P J Browning; B Ensoli; M Stürzl
Journal:  Adv Enzyme Regul       Date:  1999

9.  Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells.

Authors:  D M Lukac; J R Kirshner; D Ganem
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

10.  Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia?

Authors:  E Cesarman; E A Mesri; M C Gershengorn
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

View more
  14 in total

1.  Generation of a reporter cell line for detection of infectious varicella-zoster virus and its application to antiviral studies.

Authors:  Guan-Qing Wang; Tatsuo Suzutani; Yumiko Yamamoto; Yoshiko Fukui; Naoki Nozawa; D Scott Schmid; Ichiro Kurane; Naoki Inoue
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation.

Authors:  Fabrizio Angius; Enrica Piras; Sabrina Uda; Clelia Madeddu; Roberto Serpe; Rachele Bigi; Wuguo Chen; Dirk P Dittmer; Raffaello Pompei; Angela Ingianni
Journal:  J Antibiot (Tokyo)       Date:  2017-06-14       Impact factor: 2.649

3.  Interferon Regulatory Factor 1 and Type I Interferon Cooperate To Control Acute Gammaherpesvirus Infection.

Authors:  Wadzanai P Mboko; Michaela M Rekow; Mitchell P Ledwith; Philip T Lange; Kaitlin E Schmitz; Sean Anderson; Vera L Tarakanova
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

4.  The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production.

Authors:  Carmen M Klass; Laurie T Krug; Veronika P Pozharskaya; Margaret K Offermann
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

5.  Kaposi sarcoma-associated herpesvirus degrades cellular Toll-interleukin-1 receptor domain-containing adaptor-inducing beta-interferon (TRIF).

Authors:  Humera Ahmad; Rachel Gubbels; Erica Ehlers; Florencia Meyer; Thomas Waterbury; Rongtuan Lin; Luwen Zhang
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

6.  Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay.

Authors:  Yoshiko Fukui; Keiko Shindoh; Yumiko Yamamoto; Shin Koyano; Isao Kosugi; Toyofumi Yamaguchi; Ichiro Kurane; Naoki Inoue
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

7.  Mouse gammaherpesvirus-68 infection acts as a rheostat to set the level of type I interferon signaling in primary macrophages.

Authors:  Brittani M Wood; Wadzanai P Mboko; Bryan C Mounce; Vera L Tarakanova
Journal:  Virology       Date:  2013-05-23       Impact factor: 3.616

Review 8.  New approaches to the treatment of human herpesvirus 8-associated disease.

Authors:  Corey Casper
Journal:  Rev Med Virol       Date:  2008 Sep-Oct       Impact factor: 6.989

9.  ORF73-null murine gammaherpesvirus 68 reveals roles for mLANA and p53 in virus replication.

Authors:  J Craig Forrest; Clinton R Paden; Robert D Allen; Julie Collins; Samuel H Speck
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

10.  The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system.

Authors:  Elias G Argyris; Edward Acheampong; Fengxiang Wang; Jialing Huang; Keyang Chen; Muhammad Mukhtar; Hui Zhang
Journal:  Virology       Date:  2007-07-12       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.